Patient's own immune cells take on head and neck cancer in new trial

NCT ID NCT06190275

Recruiting now Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a new treatment called GT201, made from a patient's own tumor-fighting immune cells (TILs), combined with a PD-1 inhibitor drug. The goal is to see if this combination is safe and tolerable for 32 adults with advanced head and neck cancer that has returned or spread. The trial has two phases: first finding the right dose, then expanding to see how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GT201 (tumor-infiltrating lymphocytes) combined with a PD-1 inhibitor
What this could lead to: If successful, this could point toward a new treatment option for advanced head and neck cancer that uses the patient's own immune cells to fight tumors.
What could go wrong: This is a very early, small trial (32 people) focused on safety, not proof of effectiveness. The combination therapy may cause severe side effects, and it's unknown if it will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HNSCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HNSCC

Contacts and locations

Locations

Shanghai Ninth People's Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.